<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Select new FDA-approved anti-tuberculosis drugs and antivirals on the market in the USA since year 2017</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug class</th>
    <th>Names and notes</th>
    <th>Indications</th>
    <th>Side effects</th>
    <th>Comments</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Antiviral protein inhibitor</td>
    <td>Tecovirimat</td>
    <td>Small pox in adults and children</td>
    <td>Headache in healthy volunteers; hypoglycemia when combined with repaglinide</td>
    <td>Available through Strategic national Stockpile. Unknown efficacy in humans</td>
   </tr>
   <tr>
    <td>Endonuclease inhibitor</td>
    <td>Baloxavir marboxil</td>
    <td>Influenza up to 48 h in duration in patients 12 years of age or older</td>
    <td>No significant side effects described</td>
    <td>Single-dose completes the course of treatment, avoid co administration with antacids, laxatives, or oral supplements</td>
   </tr>
   <tr>
    <td>Non-nucleoside reverse transcriptase inhibitor</td>
    <td>Doravirine</td>
    <td>Combination therapy for HIV infection</td>
    <td>Uncommon; immune reconstitution inflammatory syndrome</td>
    <td>Do not co-administer strong cytochrome P450 enzyme inducers</td>
   </tr>
   <tr>
    <td>Monoclonal anti MDR HIV antibody</td>
    <td>Ibalizumab-uiyk</td>
    <td>MDR HIV infection</td>
    <td>Diarrhea, rash; immune reconstitution inflammatory syndrome</td>
    <td/>
   </tr>
   <tr>
    <td>Anti-hepatitis C combination drug</td>
    <td>Glecaprevir and pibrentasvir</td>
    <td>Hepatitis C infection</td>
    <td>Reactivation of hepatitis B that can result in fulminant hepatitis; worsening liver failure;</td>
    <td>Contraindicated in patients with severe liver impairment; avoid co-administering strong cytochrome P450 enzyme inducers</td>
   </tr>
   <tr>
    <td>Anti-hepatitis C combination drug</td>
    <td>Sofosbuvir/velpatasvir/voxilaprevir</td>
    <td>Hepatitis C infection</td>
    <td>Reactivation of hepatitis B that can result in fulminant hepatitis, case reports of severe bradycardia when amiodarone is co-administered; headache</td>
    <td>Not recommended in patients with moderate to severe hepatic impairment; do not co administer rifampin;</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
